[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618167":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":47,"collaborators":11,"id":51,"slug":11,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":11,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":11,"overallStatus":70,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Shanghai 10th People's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention Group","EXPERIMENTAL",null,[13],"Drug: Coenzyme I for Injection",{"label":15,"type":16,"description":11,"interventionNames":17},"Control Group","PLACEBO_COMPARATOR",[18],"Drug: NaCl (placebo)",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Coenzyme I for Injection","Subjects receive 7 consecutive days of intravenous infusion of Coenzyme I for injection.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"NaCl (placebo)","Subjects receive 7 consecutive days of intravenous infusion of NaCl(0.9%).",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Yi Zhang","CONTACT","18917686332","yizshcn@gmail.com",[36],{"facility":37,"status":11,"city":38,"state":39,"zip":11,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":11},"Shanghai Tenth People's Hospital","Shanghai","Shanghai Municipality","China",{"type":42,"coordinates":43},"Point",[44,45],121.45806,31.22222,{"lat":45,"lon":44},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Ya-Wei Xu","Senior doctor, Professor","100618167",false,"NCT07328100","Efficacy and Safety of Coenzyme I for Injection on Vascular Aging.","A Randomized, Double-blind, Parallel Controlled Clinical Trial to Evaluate the Efficacy of Coenzyme I for Injection in the Treatment of Vascular Aging（Pilot Stydy）","Inclusion Criteria:\n\n1. Ages 40-70 years;\n2. cf-PWV was abnormally elevated and above the upper limit of its age-and blood-pressure matched reference range;\n3. Systolic Blood Pressure \\\u003C 160 mmHg and ≥ 140 mmHg or Diastolic BP \\\u003C 100 mmHg ≥ 90mmHg;\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Consumption of foods or medications containing high levels of NAD+, NR, NAM, NMN, or niacin-related components (including Vitamin B3 and natural health products) within 3 months prior to screening；\n2. History of major cardiovascular or cerebrovascular events, including myocardial infarction, angina, stroke, or hospitalization for arterial revascularization；\n3. Systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg；\n4. Diagnosis of malignant tumor；\n5. Known allergy or history of severe adverse reactions to Coenzyme I injection or any of its components；\n6. History of severe allergies or infusion reactions；\n7. Women who are pregnant, breastfeeding, or planning pregnancy；\n8. Severe hepatic or renal dysfunction: ALT or AST \\> 5 times the upper limit of normal; glomerular filtration rate ≤ 30 mL\u002Fmin\u002F1.73 m²；\n9. Concurrent participation in another clinical trial without completion of the follow-up period；\n10. Other conditions deemed by the investigator as unsuitable for inclusion, such as psychiatric or psychological disorders.","ALL","40 Years","70 Years",{"count":61,"type":62},60,"ESTIMATED","INTERVENTIONAL",[65],"NA","Emerging evidence identifies vascular aging independently predicting cardiovascular events, yet effective clinical interventions remain lacking. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor whose levels decline with age, and preclinical studies suggest that boosting NAD+ can improve vascular function and structure. Preliminary clinical studies in healthy older adults indicate that supplementation with NAD+ precursors, such as nicotinamide riboside(NR) or nicotinamide mononucleotide (NMN), can reduce arterial stiffness as measured by pulse wave velocity (PWV). However, whether NAD+ supplementation can improve vascular endothelial function and exert anti-stiffening effects in patients who have already developed measurable arterial stiffness remains unknown. Based on this evidence, the investigator hypothesize that the Coenzyme I for Injection will reverse vascular aging in older adults with established arterial stiffening.",[68,69],"Vascular Aging","NAD","NOT_YET_RECRUITING","2025-12-28",{"date":73,"type":74},"2026-01-08","ACTUAL",{"date":76,"type":62},"2026-01-16",{"date":78,"type":62},"2027-12-31",{"name":5,"class":6},1]